LSE:GKP
LSE:GKPOil and Gas

3 UK Growth Companies With Up To 87% Earnings Growth

The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting global economic uncertainties. In such a climate, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those closest to the business, potentially positioning them well for resilience and future expansion.
LSE:HTG
LSE:HTGEnergy Services

UK Penny Stocks To Watch In October 2025

The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices both closing lower amid concerns over weak trade data from China, a key trading partner. Despite these broader market pressures, certain investment opportunities remain appealing to investors seeking growth potential. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond the traditional blue-chip options.
LSE:AEP
LSE:AEPFood

3 UK Dividend Stocks To Consider With Up To 6.3% Yield

Amid recent downturns in the FTSE 100 and broader UK markets, driven by weak trade data from China and global economic uncertainties, investors are increasingly seeking stability through dividend stocks. In such a climate, companies with robust dividend yields can offer a measure of predictability and income potential, making them an attractive consideration for those navigating today's volatile market landscape.
LSE:ULVR
LSE:ULVRPersonal Products

Has Unilever’s Recent Push Into Sustainability Changed Its 2025 Valuation Outlook?

If you’re holding onto Unilever stock or considering making a move, you’ve probably been watching the price charts with more than a little curiosity. Over the past month, Unilever’s shares have climbed 6.3%, brushing off some of the year’s earlier hesitation. This isn’t a stock known for wild swings, yet it has quietly rewarded patient investors with a 32.9% gain over the past three years and 26.2% over five years. The most recent uptick can be traced back to new strategic partnerships and...
LSE:GSK
LSE:GSKPharmaceuticals

Is Now the Right Time to Consider GSK After a 19% Rally?

Thinking about what to do with your GSK shares or considering whether now is the right time to jump in? You're not alone. This stock has been quietly gaining momentum, and making sense of its recent run involves more than just glancing at the chart. Over the last month, GSK gained 9.0%, and it’s up 19.0% for the year. Even looking further back, the stock has delivered a 17.0% return over the past year and a striking 55.7% over five years. While there was a slight dip of 0.3% last week, that...
LSE:BP.
LSE:BP.Oil and Gas

What Does BP’s Recent 5.8% Rally Mean for Its True Value in 2025?

If you have BP stock or are considering it for your portfolio, you are probably evaluating your next move. BP's share price has experienced notable movement recently, with a 5.8% increase in the past week, even though it declined 2.4% over the past month. Year-to-date, it has achieved a 7.9% gain, and the one-year return stands at 14.1%. Looking further back, the five-year return reaches 185.4%. These figures tend to draw attention, whether you are a long-term holder or a newcomer. Growth...
LSE:RIO
LSE:RIOMetals and Mining

Is There Now an Opportunity in Rio Tinto After Shares Surge 5.4% This Week?

If you’re trying to decide whether to buy, hold, or walk away from Rio Tinto Group stock, you’re definitely not alone right now. With shares closing at $53.25 and racking up a 5.4% gain just in the last week, investors are wondering if the surge is just the beginning or merely a blip. Zooming out, Rio Tinto has delivered 12.2% over 30 days, 11.8% year-to-date, and an impressive 84.4% return over the past five years. Those kinds of numbers don’t go unnoticed, and they have been getting more...
LSE:AZN
LSE:AZNPharmaceuticals

AstraZeneca (LSE:AZN): Fresh Growth Sparks New Valuation Debate

AstraZeneca (LSE:AZN) has delivered double-digit growth in both revenue and net income over the past year. This performance has sparked renewed discussion about its potential for long-term returns. The company’s shares have gained 12% in the past month. See our latest analysis for AstraZeneca. AstraZeneca’s share price momentum has accelerated, with an 11.8% one-month gain and 16% return over the past quarter. Recent growth and a steady stream of scientific updates seem to have rekindled...